| 查看: 1376 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
2025年药学专业求调剂
已经有1人回复
-
[求助] 流式死活染 & 单细胞门控设置被质疑，如何优化并解释？
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有130人回复
-
蛋白稳定性实验与功能实验不一致
已经有11人回复
-
第4年了，马上40了，可能我与国基确实无缘吧。。。
已经有12人回复
-
2026年申博药学专业
已经有1人回复
-
292药学调剂
已经有1人回复
-
药学专硕申博
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
【招聘】温州医科大学/附属医院/瓯江实验室李校堃院士团队诚聘博士后和科研人员
+1/195
-
【招聘】温州医科大学/附属医院/瓯江实验室李校堃院士团队诚聘博士后和科研人员
+1/191
-
三峡大学生态学招硕士调剂
+2/186
-
澳门科技大学创新工程学院诚招博士生
+2/132
-
求助紫外可见分光光度计
+1/99
-
太原科技大学材料科学与工程学院招收金属材料类博士一名
+1/82
-
沈阳工业大学-环境电化学技术研究团队-招收硕士研究生
+3/57
-
青岛大学固态电池研究团队招收材料、化学、物理等方向博士研究生
+2/46
-
2026延安大学设施蔬菜环境调控与分子机制研究团队团队招收相关专业调剂研究生
+1/45
-
中原食品实验室 & 郑州轻工业大学2026年硕士研究生联合培养调剂公告
+1/39
-
【林业专业硕士调剂1名】中国林业科学研究院
+1/36
-
【2026调剂】南方科技大学-深圳理工大学-中科院 联培086000免疫方向(26.9入学)
+1/11
-
诚挚招生（硕士+博士）
+1/9
-
shu湘潭大学化工学院招收化工、能源动力、工程热物理相关研究生调剂
+1/8
-
中国科学院上海硅酸盐研究所招聘科研助理（纳米材料与生物应用方向）
+1/7
-
天津大学利物浦福州联合学院中外合办硕士【首批offer已发出】
+1/5
-
寻找26博士生导师
+1/4
-
福建师范大学国家级人才团队招收2026年博士研究生
+1/4
-
中国民航飞行学院先进连接团队招收航空宇航、航空机械专业硕士研究生（学硕专硕均可）
+1/4
-
欧洲手性光谱方向ROA/CPL/Raman imaging招收博士研究生及联合培养生（布拉格）
+1/1
9楼2015-09-01 08:14:29
7楼2015-08-31 16:02:44
10楼2015-09-01 08:19:15
11楼2015-09-14 11:50:36
